◀ Back to EPHB2

EPHB2 — GRP

Text-mined interactions from Literome

Li et al., Oncol Rep 2010 (Carcinoma, Hepatocellular...) : GRP activated MAPK/ERK1/2 in HepG2 cells, leading to enhanced proliferation, reduced apoptosis and accelerated cell cycle progression ... The effect of GRP on ERK1/2 was effectively attenuated by the GRPR antagonist PD176252 or MEK inhibitor U0126, but not by the TNF-alpha protease inhibitor TAPI-1 or the EGFR tyrosine kinase inhibitor PD153035 ... GRP promotes the growth of HepG2 cells through interaction with GRPR co-expressed in tumor cells, and subsequently activates MAPK/ERK1/2 via EGFR independent mechanisms
Dai et al., J Biol Chem 2012 (Carcinoma, Hepatocellular...) : Both p38 MAPK promoted glucose regulated protein 78 (GRP78) expression and sustained high basal activation of PI3K/Akt and MEK/ERK are involved in the cytoprotective function of p190Met ( NC )
Endale et al., Br J Pharmacol 2012 (Thrombosis) : G-Rp1 inhibits collagen induced platelet activation and thrombus formation through modulation of early GPVI signalling events, and this effect involves VASP stimulation, and ERK2 and p38 ( -MAPK ) inhibition
Sharif et al., Mol Cell Endocrinol 1997 (Glioblastoma) : Stimulation of the glioblastoma cell line U-373MG with bombesin or gastrin releasing peptide (GRP) induced mitogenesis, measured by [ 3H ] thymidine incorporation into DNA, and stimulated the tyrosine phosphorylation of the mitogen activated protein ( MAP ) kinases ( Erk1 and Erk2 )